The incidence of pancreas cancer continues to rise in many countries. In 2017, an estimated 53,600 cases were diagnosed in the United States, representing an approximately 45% increase over the past decade. Pancreatic ductal adenocarcinoma (PDAC), which is considered incurable, accounts for more than 90% of pancreatic cancer cases.
Amid this backdrop, a panel of experts from North America and Europe discussed emerging issues in the treatment of PDAC during an OncLive Peer Exchange® program Read more . . .